v3.26.1
Warrants - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Millions
 1 Months Ended 6 Months Ended 12 Months Ended
Dec. 31, 2023
Jun. 30, 2023
Dec. 31, 2022
Jun. 30, 2026
Dec. 31, 2025
Mar. 31, 2026
Jul. 21, 2025
Dec. 31, 2024
Nov. 21, 2023
Mar. 21, 2023
Class of Warrant or Right [Line Items]                    
Warrants issued           2,753,246        
Warrants and rights outstanding, term (year)       3 months 21 days 9 months 21 days          
Common Stock [Member]                    
Class of Warrant or Right [Line Items]                    
Shares Issued, Price Per Share           $ 3.85        
PIPE Private Placement Warrants [Member]                    
Class of Warrant or Right [Line Items]                    
Class of warrant or right, exercise price of warrants or rights (in dollars per share)     $ 10.8              
Warrants issued     736,337 736,337            
Placement Agent Warrants [Member]                    
Class of Warrant or Right [Line Items]                    
Class of warrant or right, exercise price of warrants or rights (in dollars per share)     $ 13.5              
Warrants issued     21,091 21,091            
Warrants and rights outstanding, term (year)     5 years              
Ladenburg Agreement Warrants [Member]                    
Class of Warrant or Right [Line Items]                    
Class of warrant or right, exercise price of warrants or rights (in dollars per share)                   $ 5.424
Issuance of common stock under the March 2026 Public Offering Underwriters' Option, net of issuance costs (in shares)   191,689                
Warrants issued                   30,000
Warrants and rights outstanding, term (year)                   3 years
Stock issued $ 1.6 $ 3.1                
Preferred Tranche C Warrants [Member]                    
Class of Warrant or Right [Line Items]                    
Warrants and rights outstanding, term (year) [1]       2 years 4 months 28 days 2 years 10 months 28 days          
Outstanding warrants       107,115 107,115     107,115    
Preferred Tranche C Warrants [Member] | Securities Purchase Agreement [Member]                    
Class of Warrant or Right [Line Items]                    
Warrants expire date       Nov. 23, 2028            
Preferred PIPE Placement Agent Warrants [Member]                    
Class of Warrant or Right [Line Items]                    
Class of warrant or right, exercise price of warrants or rights (in dollars per share)                 $ 6.3  
Warrants issued                 850,119  
Outstanding warrants       850,119 850,119     850,119    
Preferred PIPE Series B Warrants [Member]                    
Class of Warrant or Right [Line Items]                    
Warrants Exercised       22,100            
Outstanding warrants       1,477,900 1,500,000          
Release Date Warrants [Member]                    
Class of Warrant or Right [Line Items]                    
Warrants Exercised       2,000 0          
Class of warrant or right, exercise price of warrants or rights (in dollars per share)             $ 218.75      
Enrollment Date Warrants [Member]                    
Class of Warrant or Right [Line Items]                    
Warrants Exercised       20,100 0          
Class of warrant or right, exercise price of warrants or rights (in dollars per share)             $ 175      
Private Placement [Member]                    
Class of Warrant or Right [Line Items]                    
Issuance of common stock under the March 2026 Public Offering Underwriters' Option, net of issuance costs (in shares)     736,337              
Equity offering, combined purchase price (in dollars per share)     $ 10.8              
Equity offering, premium per share (in dollars per share)     $ 1.25              
Private Placement [Member] | Preferred Tranche C Warrants [Member] | Securities Purchase Agreement [Member]                    
Class of Warrant or Right [Line Items]                    
Warrants and rights outstanding, term (year) 5 years                  
Private Placement [Member] | Preferred Tranche C Warrants [Member] | Securities Purchase Agreement [Member] | Series A-3 Preferred Stock [Member]                    
Class of Warrant or Right [Line Items]                    
Outstanding warrants       107,115            
Aggregate exercise price       $ 107.1            
Maximum [Member] | Preferred PIPE Series B Warrants [Member]                    
Class of Warrant or Right [Line Items]                    
Warrants issued             1,000,000      
Minimum [Member] | Preferred PIPE Series B Warrants [Member]                    
Class of Warrant or Right [Line Items]                    
Warrants issued             500,000      
Public Warrants [Member]                    
Class of Warrant or Right [Line Items]                    
Class of warrant or right, number of securities called by each warrant or right (in shares)       1            
Class of warrant or right, exercise price of warrants or rights (in dollars per share)       $ 115            
Warrants or rights, redemption price (in dollars per share)       0.01            
Warrants and rights outstanding, minimum share price to call (in dollars per share)       $ 180            
Warrants expire date       Oct. 22, 2026            
Private Placement Warrants [Member]                    
Class of Warrant or Right [Line Items]                    
Warrants expire date       Oct. 22, 2026            
Pre-Funded Warrants [Member]                    
Class of Warrant or Right [Line Items]                    
Class of warrant or right, exercise price of warrants or rights (in dollars per share)           0.0001        
Shares Issued, Price Per Share           $ 3.8499        
[1] Reflects a probability-weighted input derived from multiple Black-Scholes calculations. These calculations incorporate the Company’s estimated probability of survival, assuming SABS’ intellectual property yields positive results in forthcoming clinical trials, allowing the Company to continue as a going concern rather than face dissolution before 2028. The probability of survival was 57.5% and 40.0% as of June 30, 2026 and December 31, 2025, respectively.